Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527166 | 0.89 | L3MBTL1 (0.49) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL2347960 | 0.87 | KCNH2 (0.38) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL2350627 | 0.85 | KCNH2 (0.56) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL31047117 | 0.85 | KCNH2 (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL28789031 | 0.85 | KCNH2 (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL3585037 | 0.85 | KCNH2 (0.56) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL3585032 | 0.85 | KCNH2 (0.56) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL4637528 | 0.85 | KCNH2 (0.56) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL4637526 | 0.85 | KCNH2 (0.56) | ALDH1A1KCNH2SCN3ASCN1ASCN4A | |
| SCHEMBL2036282 | 0.85 | KCNH2 (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019112024-A1 | PYRROLIDINE COMPOUND | キッセイ薬品工業株式会社 | 2019-06-13 | — | — | WO | disclosed |
| EP-2125829-B1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8008293-B2 | Bicyclic oxomorpholine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2125829-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008108378-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-12 | — | — | WO | disclosed |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | OPRM1, OPRK1, OPRD1 | ALDH1A1 2062/4885KCNH2 1129/4885SCN3A 278/4885 |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | OPRM1, OPRK1, OPRD1 | ALDH1A1 1360/4885KCNH2 423/4885SCN3A 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.